DURHAM, N.C., August 20, 2026 – MedPharm, a global leader in topical and transdermal contract drug development and manufacturing, today announced that it has become an Olink® Certified Service Provider (CSP), making it the first Olink CSP in the Carolinas and one of only three in the Southeastern United States.
Meet MedPharm at CPHI Milan 2026
We’re excited to be exhibiting at CPHI Milan 2026, one of the pharmaceutical industry’s leading global events. If you’re attending, we’d love the opportunity to connect and discuss how MedPharm can help advance your topical and transepithelial drug development programs. This year, we’re also proud to be joined by our strategic partner, Purna, showcasing our integrated transatlantic capabilities from development through commercial manufacturing.
Event Details
📍 Booth: 12C69 (Hall 12)
📍 Location: Milan, Italy
📅 Dates: Tuesday, 6 October – Thursday, 8 October 2026
Whether you’re looking for support with formulation development, analytical testing, in vitro performance testing, clinical trial manufacturing, scale-up, or commercial manufacturing, our team will be available to discuss your development goals and demonstrate how our integrated approach helps de-risk programs from concept through commercialization.
Together, MedPharm and Purna provide a seamless partnership that combines scientific expertise in topical and transepithelial drug development with commercial manufacturing capabilities, helping sponsors move programs confidently from concept to market.
Stop by our booth to meet our scientists and business development team, learn about our latest capabilities, and discover how MedPharm and Purna can support your next development program.
We look forward to seeing you in Milan!
Purna and MedPharm to Establish Trans-Atlantic Partnership to Serve Global Clients
Boston, MA, February 12, 2026 – Ampersand Capital Partners, a private equity firm specializing in growth investments in the life sciences and healthcare sectors, today announced its acquisition of Purna Pharmaceuticals, a trusted provider of development and manufacturing services for liquid and semi-solid dosage forms in support of pharmaceutical industry customers.
MedPharm Welcomes Palvella Therapeutics’ Positive Topline Results from Its Phase 3 Study of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
DURHAM, N.C., March 17, 2026 – MedPharm, a global leader in topical and transdermal contract drug development and manufacturing, today welcomed the news that its partner, Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), recently announced positive topline results from its Phase 3 SELVA study of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), an investigational therapy underdevelopment for the treatment of microcystic lymphatic malformations (microcystic LMs).
MedPharm Shortlisted for Two CPHI Pharma Awards
MedPharm is pleased to announce that it has been selected as a finalist in two CPHI Pharma Award Categories.
MedPharm’s unique MedSpray® Aerosol Technology was shortlisted for the Finished Formulation category, and our MedCast model was shortlisted in the Drug Delivery Device Innovation category.
MedPharm Welcomes New Board Members, Appoints Industry Veteran Patrick Walsh as Executive Chairman
Guildford, UK and Durham, NC, February 20, 2024 – MedPharm, a global topical and transdermal CDMO, today announced several Board changes, including the appointment of Patrick Walsh as Executive Chairman. Patrick has been an Ampersand Operating Partner for the last 10 years, served as CEO of three Ampersand CDMO investments, and is currently Chairman of Alcami and ANI Pharmaceuticals.
Minor Hinson of Bourne Partners Strategic Capital (“BPSC”) also joined the MedPharm Board of Directors. Minor is the Head of Private Equity and Chief Investment Officer (CIO) of BPSC and has served on the Boards of a variety of pharmaceutical and pharma services businesses, including Covis Pharma (BPSC was co-founder with the original management team), PAI Pharmaceuticals and Eximia Research Network.
MedPharm Announces Appointment of New U.S. Director of Analytical
MedPharm, a global CDMO focused on topical and transdermal development and manufacturing, recently announced the appointment of a new U.S. Director of Analytical, Monica Germann, and the restructuring of its analytical suite in the U.S. This appointment, as well as the restructuring of the department, will create new growth opportunities for the organization, as well as efficiency gains and harmonization of analytical services across all MedPharm sites.
MedPharm currently provides a comprehensive range of analytical and bioanalytical method development and validation services to the pharmaceutical industry. This department restructure, which includes combining MedPharm’s analytical and bioanalytical teams, will allow the CDMO to build on its existing LC-MS/MS, LCUV, UPLC, and qRT-PCR testing services.
MedPharm collaborates with Mosanna to develop new drug to tackle Metabolic Obstructive Sleep Apnea
MedPharm, a global provider of contract topical and transdermal formulation development and manufacturing services, is pleased to announce that it will support Swiss Biotech company, Mosanna Therapeutics, in the development of a nasal spray (MOS-118) aimed at treating Metabolic Obstructive Sleep Apnea (MOSA).
The collaboration will focus on advancing MOS-118 into clinical development. Mosanna is developing MOS-118 to prevent the airway from collapsing during sleep in a disease that affects up to 1 billion globally. The repeated partial or complete obstruction of the upper airway during sleep is associated with adverse metabolic and cardiovascular events and can severely impact the quality of life for patients.
Successful MHRA Audit of MedPharm Guildford
MedPharm, a global Contract Development and Manufacturing Organization that specializes in topical and transdermal drug product development, recently completed a Medicines and Healthcare products Regulatory Agency (MHRA) GMP audit of its Guildford locations. We are happy to announce there were no critical or major findings from the audit.
These evaluations of MedPharm’s systems and compliance with regulatory standards are further confirmation of MedPharm’s commitment to providing the gold standard in topical development and manufacturing services.
To learn more about MedPharm’s capabilities, view our virtual facility tours or contact our team today.